FCPM III Services B.V. Acquires 1.49 Million Shares of RAPT Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 22 2026
0mins
Source: Fool
- Share Acquisition: On February 17, 2026, FCPM III Services B.V. disclosed the acquisition of 1,489,096 shares of RAPT Therapeutics, valued at approximately $46.24 million, indicating strong confidence in the company's future prospects.
- Market Value Increase: The total value of FCPM's position rose by $53.22 million at quarter-end due to trading activity and changes in RAPT's share price, reflecting market recognition of RAPT's potential.
- Acquisition Context: RAPT Therapeutics was recently acquired by GSK for $58 per share, nearly a 90% premium over the estimated average purchase price of $31 last quarter, indicating a significant reassessment of its asset value.
- Strategic Implications: This transaction represents not only an investment in a clinical-stage biotech company but also a confidence in the asset's potential strategic appeal, showcasing FCPM's strategic positioning in the high-conviction biotech sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
